

1 **Research article: Single Channel Electrocardiography Optimizes the Diagnostic**  
2 **Accuracy of Bicycle Ergometry**

3 Running title: Recent advances in IHD diagnosis

4

5 **Authors' list: Basheer Abdullah Marzoog<sup>1,\*</sup>, Magomed Abdullaev<sup>1</sup>, Alexander**  
6 **Suvorov<sup>1</sup>, Peter Chomakhidze<sup>1</sup>, Daria Gognieva<sup>1</sup>, Nina Vladimirovna Gagarina<sup>2</sup>,**  
7 **Natalia Mozzhukhina<sup>3</sup>, Sergey Vladimirovich Kostin<sup>4</sup>, Afina Aftandilovna**  
8 **Bestavashvili<sup>1</sup>, Ekaterina Fominykha<sup>2</sup>, Philipp Kopylov<sup>1</sup>**

9 <sup>1</sup> World-Class Research Center «Digital Biodesign and Personalized Healthcare», I.M.  
10 Sechenov First Moscow State Medical University (Sechenov University), 119991 Moscow,  
11 Russia; postal address: Russia, Moscow, 8-2 Trubetskaya street, 119991.

12 <sup>2</sup> University clinical Hospital number 1, Radiology department, I.M. Sechenov First Moscow  
13 State Medical University (Sechenov University), 119991 Moscow, Russia; postal address:  
14 Russia, Moscow, 8-2 Trubetskaya street, 119991.

15 <sup>3</sup> University clinical Hospital number 1, Health Management Clinic, I.M. Sechenov First  
16 Moscow State Medical University (Sechenov University), 119991 Moscow, Russia; postal  
17 address: Russia, Moscow, 8-2 Trubetskaya street, 119991.

18 <sup>4</sup> National Research Ogarev Mordovia State University. Russia. Republic of Mordovia.  
19 Saransk. Bolshevistskaya str. 68, Saransk. Mordovia Republic. 430005.

20

21 \*Corresponding author: Basheer Abdullah Marzoog, M.D., Ph.D. cardiology student at  
22 Sechenov First Moscow State Medical University at the World-Class Research Center  
23 "Digital biodesign and personalized healthcare". (marzug@mail.ru, +79969602820).  
24 Address: Russia, Moscow, 8-2 Trubetskaya street, 119991. Postal address: Russia, Moscow,  
25 8-2 Trubetskaya street, 119991. ORCID: 0000-0001-5507-2413, Scopus ID: 57486338800

26

27 Competing interests: No competing interests regarding the publication.

28

29 "Posted history: This manuscript was previously posted to MedRxiv: doi: [https://doi.org/](https://doi.org/10.1101/2024.04.20.24306122)  
30 [10.1101/2024.04.20.24306122](https://doi.org/10.1101/2024.04.20.24306122)"

31

32

33 **Abstract**

34 **Background:** Ischemic heart disease (IHD) has the highest mortality rate in the globe. This  
35 returns to the poor diagnostic and therapeutic strategies including the early prevention  
36 methods.

37 **Aims:** To assess the changes in the single channel electrocardiography (SCECG) at rest and  
38 on exercise test in patients with vs without IHD confirmed by stress computed tomography  
39 myocardial perfusion (CTP) imaging with vasodilatation stress-test.

40 **Objectives:** IHD frequently have preventable risk factors and causes that lead to the disease  
41 appearance. However, the lack of the proper diagnostic and prevention tools remains a global  
42 challenge in our era despite the current scientific advances.

43 **Material and methods:** A single center observational study included 38 participants from  
44 Moscow. The participants aged  $\geq 40$  years and given a written consent to participate in the  
45 study. Both groups, G1=19 with vs G2=19 without post stress induced myocardial perfusion  
46 defect, passed consultation by cardiologist, anthropometric measurements, blood pressure and  
47 pulse rate, echocardiography, cardio-ankle vascular index, performing bicycle ergometry,  
48 recording 3-minutes SCECG (using CARDO-QVARK ) before and just after bicycle  
49 ergometry, and then performing CTP. The LASSO regression with nested cross-validation  
50 was used to find association between CARDO-QVARK parameters and the existence of the  
51 perfusion defect. Statistical processing carried out using the R programming language v4.2  
52 and Python v.3.10 [^R].

53 **Results:** The CARDO-QVARK parameters analysis have a specificity 63.2 % [95 %  
54 confidence interval (CI); 0.391 ; 0.833], sensitivity 73.7 % [95 % CI ; 0.533 ; 0.929], area  
55 under the curve (AUC) 68.4 % [95 % CI ; 0.527 ; 0.817] in compare to bicycle ergometry  
56 (AUC; 55.3 %), based on our study results.

57 **Conclusion:** The SCECG have significantly higher diagnostic accuracy in compare to bicycle  
58 ergometry. CARDO-QVARK has the potential to improve the diagnostic accuracy of the  
59 bicycle ergometry.

60 **Other:** Further investigations required to uncover the hidden capabilities of CARDO-  
61 QVARK in the diagnosis of ischemic heart disease.

62 **Keywords:** IHD, Single channel electrocardiography, CTP, Prevention, Risk Factors, Stress  
63 Test, Machine Learning Model

64

65

66

## 67 **Introduction**

68 Ischemic heart disease remains the leading challenge in terms of mortality and morbidity  
69 despite the advances in the used methods for diagnosis and prevention. However, the early  
70 prevention in terms of evaluation of the ischemic heart disease in early period still  
71 underestimated. The current attention of the scientists paid to the prevention rather than  
72 diagnosis and treatment. In this manner, the scientific community developed several cost-  
73 effective methods to be confirmed for clinical use for early prevention of ischemic heart  
74 disease, including the use of the single channel electrocardiography and exhaled breath  
75 analysis in coronary heart disease prevention <sup>[1]</sup>.

76 Ischemic heart diagnosis using single channel electrocardiography (ECG) remains in the  
77 development stage and require further elaboration in the context of the sensitivity and  
78 specificity. Several kinds of single channel ECG has been used in the clinical trials including  
79 CARDO-QVARK , Apple Watch, Kardia, Zio, BioHarness, Bittium Faros and Carnation  
80 Ambulatory Monitor <sup>[1-8]</sup>. Single channel ECG has been used to diagnosis myocardial  
81 infarction and monitoring patients with chronic heart disease and heart failure as well as to  
82 classify heartbeat <sup>[9-11]</sup>.

83 Currently there are several kinds of single channel ECG used for commercial purposes and  
84 clinical trials. The accuracy and quality of these single channel ECGs various. The uses of  
85 single channel ECGs are various including distant monitoring of patients with arrhythmias, as  
86 a Holter monitoring, and for monitoring for chronic heart failure <sup>[12, 13, 22, 14-21]</sup>. The currently  
87 available single channel ECGs in the market include Apple Watch, Kardia, Zio, Cardiostat,  
88 BioHarness, Bittium Faros and Carnation Ambulatory Monitor <sup>[13, 23]</sup>.

89 Single-channel ECG has key features that can aid in diagnosing ischemic heart disease  
90 include detecting ischemia through ECG alterations, hemodynamic changes, and clinical  
91 signs and symptoms <sup>[24]</sup>. Additionally, vectorcardiography, a technique that records cardiac  
92 electrical activity as closed loops, can be useful for training in electrocardiography and  
93 detecting cardiac ischemia <sup>[24, 25]</sup>. Portable and fast electrode placement devices allow for  
94 good-quality ECG tracings, making single-channel ECG accessible and efficient <sup>[24]</sup>.

95 In comparison of single-channel ECG to multi-channel ECG in detecting ischemic heart  
96 disease shows that modern ECG systems with vector-based electrocardiography can improve  
97 the detection of ECG alterations typical for ischemia compared to the conventional 12-lead  
98 ECG <sup>[26]</sup>. Single-channel consumer ECG devices, such as smartwatches, can be useful for  
99 detecting and monitoring arrhythmias but have limitations in detecting ST-segment  
100 deviations indicating myocardial infarction or ischemic episodes <sup>[27]</sup>.

101 The usage of single channel in ischemic heart disease has not been previously investigated  
102 and requires further elucidation.

### 103 **Material and methods**

104 A cohort, prospective single center cohort study included 38 participants. According to the  
105 results of the CTP, the participants divided in to two groups. The first group participants  
106 without stress induced myocardial perfusion defect and the second group with stress induced  
107 myocardial perfusion defect on the CTP. The participants are randomly chosen. A written  
108 consent has been taken from the participants. The study registered on clinicaltrials.gov  
109 (NCT06181799), and the study approved by the ethical commitment of the Sechenov  
110 University, Russia, from “Ethics Committee Requirement № 19-23 from 26.10.2023”.

111 The study evaluated continuous and categorical variables. The continuous variables included;  
112 age, pulse at rest, systolic blood pressure (SBP) at rest, diastolic blood pressure (DBP) at rest,  
113 body weight, height, maximum heart rate (HR) on physical stress test, watt (WT) on physical  
114 stress test, metabolic equivalent (METs) on physical stress test, reached percent on physical  
115 stress test , ejection fraction (EF %) on echocardiography, estimated vessel age, right cardio-  
116 ankle vascular index (R-CAVI), left Cardio-ankle vascular index (L-CAVI), right ankle-  
117 brachial index (RABI), left ankle-brachial index (LABI), mean SBP brachial (SBPB) (=right  
118 SBPB+ left SBPB)/2), mean DBPB (=right DBPB + left DBPB)/2), BP right brachial  
119 (BPRB) =(SBP+DBP)/2), BP left brachial (BPLB) =(SBP+DBP)/2), mean BPB =(BPRB+  
120 BPLB)/2), BP right ankle (BPRA) =(SBP+DBP)/2), BP left ankle (BPLA)  
121 =(SBP+DBP)/2), mean BPA =(BPRA+ BPLA) /2), mean ankle-brachial index (ABI), right  
122 brachial pulse (RTb), left brachial pulse (LTb), mean Tb =(LTb+ RTb)/2), right brachial-  
123 ankle pulse (Tba), left brachial-ankle pulse (Tba), mean Tba (= left Tba+right Tba)/2),  
124 length heart-ankle (Lha in cm), heart-ankle pulse wave velocity (haPWV; m/s),  $\beta$ -stiffness  
125 index from PWV, creatinine ( $\mu\text{mol/L}$ ) , and eGFR (2021 CKD-EPI Creatinine). The  
126 categorical variables included; gender, obesity stage, smoking, concomitant disease,  
127 atherosclerosis of the coronary artery, hemodynamically significant (>60%), myocardial  
128 perfusion defect after stress ATP, myocardial perfusion defect before stress ATP,  
129 atherosclerosis in other arteries (Yes/No), brachiocephalic, hypertension (AH), stage AH,  
130 degree AH, risk of cardiovascular disease (CVD), stable coronary artery disease (SCAD),  
131 functional class (FC) by WT, FC by METs, reaction type to stress test(positive/negative), and  
132 reason of discontinuation of the stress test.

133 The study used the following SCECG parameters:

- 134 • QTc duration (Bazett’s formula);

135 • amplitude parameters (JA is the amplitude at point J in microV, TA is the amplitude of the  
136 T-wave in microV, PAn is the amplitude of the negative P-wave in microV);  
137 • indices of asymmetry SBeta, Beta (ratio of the maximum modulus of the derivative value at  
138 the leading front of the T-wave to the maximum modulus of the value at the trailing front of  
139 the T-wave);  
140 • spectral integrals of energy of R and T waves: QRS1energy (leading front of R—1st  
141 derivative), QRS12energy (trailing front of R—1st derivative), QRS2energy (R-wave as a  
142 whole—2nd derivative), TE1 (T-wave as a whole) - (the integral is calculated as the sum of  
143 energies at all points of the corresponding region );  
144 • spectral integral set by the frequency grid 2 to 4 Hz, 4 to 8 Hz (QRSE1, QRSE2);  
145 • frequency of the maximum energy of the leading and trailing fronts of the R wave (RonsF,  
146 RoffsF);  
147 • rhythm variability (SDNN);  
148 • ECG time markers: PpeakN, Rpeak, Speak, Tpeak, Tons, Toffs.  
149 ECG time intervals were calculated not from the beginning of the cardiac cycle, but from a  
150 point on the isoline, two-thirds of the duration of the mean R-R interval from the previous R-  
151 wave (so called—Calculated point). All parameters, except for the indicators of rhythm  
152 variability, were averaged taking into account the pulse rate. Rhythm variability indicators  
153 were evaluated by the program without averaging the values. Thus, the time parameters of the  
154 ECG took into account not only the morphology of the cardiac cycle, but also changes the  
155 heart rate. Considering that averaged values were taken into account, a longer recording  
156 provides the most accurate parameters. This includes markers of the beginning or the end of  
157 the wave (Pfi, QRSst, QRSfi), the shift of the negative or positive maximum value relative to  
158 the beginning of the averaged complex (PpeakN, Rpeak, Speak, Tpeak), as well as the  
159 maximum slope of the waves (Tons, Toffs). QRSfi is the time interval from the calculated  
160 point to the end of the QRS complex, expressed in ms. Tpeak is the time interval from the  
161 calculated point to the peak of the T wave. Toffs is the time interval from the calculated point  
162 to the point of maximum steepness of the descending knee of the T wave <sup>[28]</sup>.  
163 Taking into account that the position of the calculated point depends on the R-R interval, it is  
164 possible to minimize the effect of heart rate on the time parameters of the cardiac cycle.  
165 These time parameters take into account not only the morphology of the QRS complex or T-  
166 wave, but also the temporal features of the entire cardiac cycle.

167 After logistic regression analysis including more than 200 ECG parameter listed above, the  
168 artificial intelligence method was used to find combinations with the highest accuracy for  
169 IHD determination.

### 170 **Criteria for the study participants**

171 The inclusion criteria included;

- 172 1. Participants age  $\geq$  40 years.
- 173 2. Participants with intact mental and physical activity.
- 174 3. Written consent to participate in the study, take blood samples, and anonymously  
175 publish the results of the study.
- 176 4. The participants of the control group are individuals without coronary artery disease,  
177 confirmed by the absence of the myocardial perfusion defect on the adenosine  
178 triphosphate stress myocardial perfusion computed tomography ((by using contrast  
179 enhanced multi-slice spiral computed tomography (CE-MSCT) using adenosine  
180 triphosphate (ATP)), and confirmed by medical history, previous medical tests, and  
181 retrospective interview of participants.
- 182 5. The participants of the experimental group are individuals with coronary artery  
183 disease, confirmed by myocardial perfusion defect on the adenosine triphosphate  
184 stress myocardial perfusion computed tomography, and confirmed by medical history,  
185 previous medical tests, and retrospective interview of participants.

186 Exclusion criteria:

- 187 1. Poor single-channel ECG and pulse wave recording quality
- 188 2. Failure of the stress test for reasons unrelated to heart disease
- 189 3. Reluctance to continue participating in the study.

190 Non-inclusion criteria

- 191 1. Pregnancy.
- 192 2. Diabetes mellitus
- 193 3. Presence of signs of acute coronary syndrome (myocardial infarction in the last two  
194 days), history of myocardial infarction;
- 195 4. Active infectious and non-infectious inflammatory diseases in the exacerbation phase;
- 196 5. Respiratory diseases (bronchial asthma, chronic bronchitis, cystic fibrosis);
- 197 6. Acute thromboembolism of pulmonary artery branches;
- 198 7. Aortic dissection;
- 199 8. Critical heart defects;
- 200 9. Active oncopathology;

- 201 10. Decompensation phase of acute heart failure;
- 202 11. Neurological pathology (Parkinson's disease, multiple sclerosis, acute psychosis,  
203 Guillain-Barré syndrome);
- 204 12. Cardiac arrhythmias that do not allow exercise ECG testing (Wolff-Parkinson-White  
205 syndrome, Sick sinus syndrome, AV block of II-III-degree, persistent ventricular  
206 tachycardia);
- 207 13. Diseases of the musculoskeletal system that prevent passing a stress test (bicycle  
208 ergometry);
- 209 14. Allergic reaction to iodine and/or adenosine triphosphate.

#### 210 **Data collection**

211 All participants at rest pass registration of S-ECG and pulse wave before (during 3 minutes)  
212 and just after (during 3 minutes) physical stress test (bicycle ergometry) using a portable  
213 single-channel recorder (CARDO-QVARK ; Russia, Moscow) <sup>[29]</sup>. The SCECG and pulse  
214 wave results interpreted using machine learning models developed by the Sechenov  
215 University team <sup>[29, 30]</sup>.

216 Both groups pass a vessel stiffness test and pulse wave recording as well as vascular age by  
217 using Fukuda Denshi device (VaSera VS-1500; Japan). Cuffs placed to assess the vascular  
218 stiffness (CAVI parameter) and the vascular age as well as the ankle-brachial index. <sup>[31]</sup>

219 Subsequently, participants pass exercise bicycle ergometry test (SCHILLER CS200 device;  
220 Bruce protocol or modified Bruce protocol). According to the results metabolic equivalent;  
221 Mets-BT (BT), the angina functional class (FC) in participants with positive stress test results  
222 determined. During the bicycle ergometry, the participants monitored with 12-lead ECG and  
223 manual blood pressure measurement, 1 time each 2 minutes. The rest time ECG and blood  
224 pressure monitoring continue for at least five minutes after the end of the stress bicycle  
225 ergometry test.

226 The procedure discontinues if: an increase in systolic blood pressure  $\geq 220$  mmHg,  
227 horizontal or down sloping ST segment depression on the ECG  $\geq 1$  mm, typical heart pain  
228 during test, ventricular tachycardia or atrial fibrillation, or other significant heart rhythm  
229 disorders were found. Moreover, stop the procedure if the target heart rate (86% of the 220-  
230 age) is reached.

231 Before performing CTP, all the participants present results of the venous creatinine level,  
232 eGFR (estimated glomerular filtration rate) according to the 2021 CKD-EPI Creatinine  $> 30$   
233 ml/min/1,73 m<sup>2</sup>, according to the recommendation for using this formula by the National  
234 kidney foundation and the American Society of Nephrology <sup>[32-35]</sup>.



235 The participants of both groups got catheterization in the basilar vein or the radial vein for  
236 injection of contrast and ATP to performed pharmacological stress test to the heart by  
237 increasing heart rate during the stressed myocardial perfusion computer tomography imaging.  
238 Computer tomography was performed on Canon scanner with 640 slice, 0,5 mm thickness of  
239 slice, with contrast (Omnipaque, 50 ml), injected two times: in rest to get images for  
240 myocardial perfusion before test, and in 20 mints just after ATP had been injected in dose  
241 according to body weight.

242 The results of the myocardial perfusion considered positive if there was a perfusion defect  
243 after stress test or worsen the already existing at the rest phase perfusion defect.

244 Statistical processing was carried out using the R programming language v4.2 and Python  
245 v.3.10 [^R] <sup>[36, 37]</sup>. Statistically significant values considered at  $p < 0.05$ .

#### 246 **Statistical analysis**

247 For quantitative parameters, the nature of the distribution (using the Shapiro-Wilk test), the  
248 mean, the standard deviation, the median, the interquartile, the 95% confidence interval, the  
249 minimum and maximum values were determined. For categorical and qualitative features, the  
250 proportion and absolute number of values were determined.

251 Comparative analysis for normally distributed quantitative traits was carried out on the basis  
252 of Welch's t-test (2 groups); for abnormally distributed quantitative traits, using the Mann-  
253 Whitney U-test (2 groups).

254 Comparative analysis of categorical and qualitative features was carried out using the Pearson  
255 X-square criterion, in case of its inapplicability, using the exact Fisher test.

256 For Single channel ECG values, pre-load values (prefixed with "  $q0_$ " were used, and deltas  
257 between immediately after exertion ( $q1$ ) and after 2nd single channel ECG record, were  
258 calculated:

259

$$q0 = \textit{before}$$

$$q1 = \textit{after 1}$$

260 Calculation of deltas:

$$dltq_{01} = q1 - q0$$

#### 261 **Outcome and feature selection**

262 In order to assess the impact of factors on outcomes due to the small number of observations,  
263 it was decided to abandon the classic univariate and subsequent stepwise or multivariate



264 regression analysis. The effect of exhaled air and CARDO-QVARK on the target variable  
265 was assessed using a mathematical modeling conveyor.

266 Due to the small number of observations, the so-called external cross-validation was used to  
267 assess the model's performance to select predictors. Selection was made among the predictor  
268 levels before the sample (CARDO-QVARK results), and then the delta for CARDO-QVARK  
269 results, as calculated above.

270 The data was randomly split with a mixing procedure into 3 parts. Each part became a  
271 validation array, and the remaining 2/3 became a training array. Thus, 3 different models  
272 were trained on each iteration, and none of the models were validated on the same data as  
273 they were trained.

274 This iteration was repeated 500 times with different options for splitting the data into 3 parts  
275 <sup>[38]</sup>. This approach allows us to draw indirect conclusions about the possibility of generalizing  
276 the results of model quality into larger samples.

277 The purpose of this method was to select the predictors with the highest normalized  
278 coefficients for each constructed model, which was a logistic regression with L1  
279 regularization (Lasso regression). For each model that showed the quality of the AUC  
280 classifier above 0.75 in the validation part of the sample, the selected predictors and the  
281 corresponding coefficients were taken. For each predictor, the coefficients were taken  
282 modulo, then averaged, after which the 5 predictors with the highest coefficients were used  
283 for subsequent validation.

284 The validation process consisted of using only 5 selected predictors to build the model. In  
285 other respects, 3-fold cross-validation with data mixing with subsequent evaluation of the  
286 results of 3 classifiers was also used. This was possible because the hyperparameters of the  
287 classifiers were the same, and all 3 validation samples together gave all the data in the total  
288 sample.

## 289 **Results**

290 The characteristics of the sample described in the tables bellow. (*Table 1A-B*)

291 Table 1A: Categorical variables presented in absolute and relative values of the study for true  
292 incidence of the stated factor. Abbreviations: CPT; stress myocardial perfusion computer  
293 tomography imaging.  $X^2$  test used as a comparative test. \* Values statically significant  
294 difference. Abbreviations: METs; metabolic equivalent.

Index	Factor	Group 1 (n=19). Positive CTP	Group 2 (n=19). Negative	p
-------	--------	---------------------------------	-----------------------------	---

			CTP	
Gender	F	10 (52.6%)	7 (36.8%)	0.328
	M	9 (47.4%)	12 (63.2%)	
Obesity stage	1 degree	3 (15.8%)	3 (15.8%)	>0.999
	Normal	8 (42.1%)	9 (47.4%)	
	Overweight	8 (42.1%)	7 (36.8%)	
Atherosclerotic vascular (Namely)	Carotid	1 (9.1%)	0 (0.0%)	>0.999
	Carotid. Brachiocephalic bifurcation	10 (90.9%)	4 (100.0%)	
Stage of hypertension	I	2 (25.0%)	1 (7.1%)	0.179
	II	3 (37.5%)	11 (78.6%)	
	III	3 (37.5%)	2 (14.3%)	
Degree of hypertension	Degree 1	4 (50.0%)	7 (50.0%)	0.366
	Degree 2	1 (12.5%)	5 (35.7%)	
	Degree 3	3 (37.5%)	2 (14.3%)	
Risk of cardiovascular disease	High	3 (15.8%)	7 (36.8%)	0.486
	Low	7 (36.8%)	4 (21.1%)	
	Moderate	7 (36.8%)	7 (36.8%)	
	Very high	2 (10.5%)	1 (5.3%)	
Blood pressure reaction type on stress test	Asthenic	2 (10.5%)	1 (5.3%)	0.302
	Hypertonic	1 (5.3%)	1 (5.3%)	
	Hypotonic	3 (15.8%)	0 (0.0%)	

	Mild Hypertonic	1 (5.3%)	1 (5.3%)	
	Normotonic	12 (63.2%)	16 (84.2%)	
Watt	75	4 (21.1%)	7 (36.8%)	0.167
	100	8 (42.1%)	2 (10.5%)	
	125	4 (21.1%)	3 (15.8%)	
	150	1 (5.3%)	2 (10.5%)	
	175	0 (0.0%)	2 (10.5%)	
	200	1 (5.3%)	3 (15.8%)	
	250	1 (5.3%)	0 (0.0%)	
Functional class by Watt	FC-I	2 (40.0%)	3 (42.9%)	>0.999
	FC-II	3 (60.0%)	4 (57.1%)	
Functional class by METs	FC-I	1 (20.0%)	3 (42.9%)	0.735
	FC-II	4 (80.0%)	3 (42.9%)	
	FC-III	0 (0.0%)	1 (14.3%)	
Reaction type to stress test (positive/negative)	Negative	8 (42.1%)	9 (47.4%)	0.593
	Positive	5 (26.3%)	7 (36.8%)	
	Suspected	6 (31.6%)	3 (15.8%)	
Reason of discontinuation of the stress test	Horizontal ST depression >1mm	2 (10.5%)	4 (21.1%)	0.660
	Reach goal HR	17 (89.5%)	15 (78.9%)	
Tolerance to exertion on stress test	Close to high	2 (10.5%)	2 (10.5%)	0.830
	High	2 (10.5%)	2 (10.5%)	

	Low	0 (0.0%)	1 (5.3%)	
	Moderate	13 (68.4%)	10 (52.6%)	
	Very high	2 (10.5%)	4 (21.1%)	
Biological estimated vascular age	High	10 (52.6%)	9 (47.4%)	0.746
	Normal	9 (47.4%)	10 (52.6%)	
CKD stage	I	6 (31.6%)	10 (52.6%)	0.078
	II	9 (47.4%)	9 (47.4%)	
	IIIa	4 (21.1%)	0 (0.0%)	

295

296 Table 1B: The continuous variables of the sample presented as a mean  $\pm$  standard deviation  
 297 (Std. div.), Student test as independent variables used. \* Values statically significant  
 298 difference. Abbreviations: SBP; systolic blood pressure, DBP; diastolic blood pressure, BMI,  
 299 body mass index, HR; heart rate, METs; metabolic equivalent, R-CAVI; right Cardio-ankle  
 300 vascular index, L-CAVI; left Cardio-ankle vascular index, RABI; right ankle-brachial index,  
 301 LABI; left ankle-brachial index, SBP B; systolic blood pressure brachial, DBP B; diastolic  
 302 blood pressure brachial, BP RB; blood pressure right brachial, BP RA ; blood pressure right  
 303 ankle, BP LA; blood pressure left ankle, BP A; blood pressure ankle, ABI; ankle-brachial  
 304 index, RTb; right brachial pulse, LTb; left brachial pulse, Tb; mean brachial pulse, Tba; mean  
 305 brachial-ankle pulse, Lha (cm); length heart-ankle, haPWV (m/s); heart-ankle pulse wave  
 306 velocity.

Index	Group 1 (n=19). Positive CTP. Mean $\pm$ Std. div.	Group 2 (n=19). Negative CTP. Mean $\pm$ Std. div.	p
Age	56.9 $\pm$ 6.2	60.6 $\pm$ 12.1	0.238
Pulse rest	73.2 $\pm$ 9.6	71.3 $\pm$ 11.1	0.578
SBP rest	124.4 $\pm$ 9.4	120.6 $\pm$ 14.8	0.354
DBP rest	79.1 $\pm$ 11.1	76.6 $\pm$ 8.2	0.429
Body weight	77.8 $\pm$ 17.4	74.0 $\pm$ 10.6	0.4

			18
Height	173.2 ± 10.3	169.4 ± 8.9	0.2 40
BMI	25.8 ± 4.3	25.9 ± 4.1	0.9 39
Goal heart rate (HR)	163.1 ± 6.2	159.4 ± 12.1	0.2 38
Maximum HR	149.5 ± 11.2	146.7 ± 19.7	0.7 48
Reached % of the target HR on stress test	91.8 ± 8.2	92.6 ± 14.9	0.6 65
METs	6.7 ± 2.0	6.5 ± 2.1	0.7 15
Ejection fraction (%)	64.6 ± 4.1	65.3 ± 5.4	0.7 26
Biological estimated vessel age	58.1 ± 7.6	62.6 ± 13.9	0.2 22
R-CAVI	8.5 ± 0.8	9.1 ± 1.8	0.2 92
L-CAVI	8.5 ± 0.7	9.0 ± 1.7	0.2 31
RABI	1.2 ± 0.1	1.1 ± 0.1	0.1 81
LABI	1.2 ± 0.1	1.1 ± 0.1	0.0 82
Mean SBP B	130.1 ± 8.7	133.2 ± 16.2	0.4 65
Mean DBP B	82.9 ± 8.4	83.5 ± 9.0	0.8 17
BP RB (= (SBP+DBP)/2)	100.7 ± 10.0	102.8 ± 14.0	0.5 89
BP LB (= (SBP+DBP)/2)	101.8 ± 10.6	103.7 ± 12.7	0.6 31

Mean BP B= (BP RB+ BP LB )/2	101.3 ± 10.1	103.3 ± 13.2	0.6 03
BP RA (=(SBP+DBP)/2)	105.3 ± 10.7	108.3 ± 14.1	0.4 73
BP LA (=(SBP+DBP)/2)	106.6 ± 9.6	106.9 ± 11.1	0.9 26
Mean BP A= (BP RA + BP LA )/2	106.0 ± 9.6	107.6 ± 12.1	0.6 47
Mean ABI=(RABI+LABI)/2	1.2 ± 0.1	1.1 ± 0.1	0.1 01
RTb	79.4 ± 8.9	78.7 ± 11.5	0.8 39
LTb	73.3 ± 6.5	74.8 ± 10.7	0.5 99
Mean Tb =( RTb+ LTb)/2	76.3 ± 7.0	76.8 ± 10.8	0.8 88
Right Tba	88.5 ± 10.9	77.4 ± 22.1	0.1 25
Left Tba	87.7 ± 9.0	79.0 ± 20.8	0.1 44
Mean Tba =( Right Tba+ Left Tba)/2	88.1 ± 9.8	78.2 ± 21.3	0.1 29
Lha (cm)	150.8 ± 8.4	147.7 ± 7.2	0.2 40
haPWV (m/s)	0.9 ± 0.1	1.0 ± 0.2	0.2 34
β-stiffness index from PWV	3.0 ± 0.6	3.3 ± 1.2	0.6 86
Creatinine (µmol/L)	83.9 ± 11.9	86.4 ± 19.4	0.6 36
eGFR (2021 CKD-EPI Creatinine)	84.5 ± 13.7	79.6 ± 17.4	0.3 45

308 **The diagnostic accuracy of the bicycle ergometry**

309 We examined the diagnostic accuracy of a standard exercise test on a bicycle ergometer. In  
310 the ROC analysis, where the predictor was the result of a sample with the results of the  
311 physical exertion “Reaction\_type” = 'Positive', and the target variable was  
312 Myocardial\_perfusion\_defect\_after\_stress\_ATP, the following results were obtained. (*Table*  
313 2)

314 Table 2: The quality of the bicycle ergometry appeared quite low in our cohort.

Chars	Point estimate	95%CI
AUC	0.553	[0.406 ; 0.695]
Sensitivity	0.263	[0.067 ; 0.474]
Specificity	0.632	[0.409 ; 0.833]
Negative predictive value	0.462	[0.269 ; 0.654]
Positive predictive value	0.417	[0.143 ; 0.714]

315

316 **CARDO-QVARK Feature selection with cross-validation**

317 After performing pipeline for feature selection using 500 iterations with 3-fold outer cross-  
318 validation , 87 best models were selected, showing  $AUC \geq 0.9$  for the test set. All models  
319 were aggregated with their respective absolute coefficients, and then the median estimate of  
320 the coefficients for each feature was calculated. Below are the selected 20 predictors (the  
321 final model included the first 5). (*Table 3*)

322 Table 3: The 20 most statically significant features according to the build model. Dltq\_01  
323 indicates the difference between the selected single channel ECG features immediately after  
324 the stress minus the selected features before the stress test.

	Feature	Lasso absolute coefficient
1.	<b>dltq_01_Pan...31</b>	0.589804
2.	<b>dltq_01_SA</b>	0.509832
3.	<b>dltq_01_JA</b>	0.37366
4.	<b>dltq_01_TE1</b>	0.270038
5.	<b>dltq_01_TpTe</b>	0.258854



6.	<b>dltq_01_HFNoise</b>	0.248446
7.	<b>dltq_01_PpeakN</b>	0.206324
8.	<b>dltq_01_QRS11energy</b>	0.190459
9.	<b>dltq_01_TA</b>	0.15963
10.	<b>dltq_01_Sbeta</b>	0.150864
11.	<b>dltq_01_TE3</b>	0.138504
12.	<b>dltq_01_Tenergy</b>	0.125174
13.	<b>dltq_01_TE4</b>	0.116375
14.	<b>dltq_01_Tpenergy</b>	0.106516
15.	<b>dltq_01_QTc</b>	0.102957
16.	<b>dltq_01_TE2</b>	0.102495
17.	<b>dltq_01_HFQRS</b>	0.090197
18.	<b>dltq_01_SDNN</b>	0.082806
19.	<b>dltq_01_QRSE1</b>	0.082143
20.	<b>dltq_01_QRSw</b>	0.063462

325

326 The model was then rebuilt as follows. The top 5 predictors from *Table 3* were with the most  
 327 mathematical importance according to the built model taken and included in the new  
 328 LASSO regression model.

329 Then the leave-one-out cross-validation procedure was performed, which allowed us to  
 330 obtain approximate estimates of sensitivity, specificity, positive and negative prognostic  
 331 value. At each iteration of leave-one-out cross-validation, the quantitative predictors were  
 332 normalized.

333 The quality of the classification is shown in the table below. (*Table 4*)


334 Table 4: The quality of the single channel ECG in the diagnosis of ischemic heart disease  
 335 using the CARDO-QVARK.

Chars	Point estimate	95%CI
AUC	0.684	[0.527 ; 0.817]
Sensitivity	0.737	[0.533 ; 0.929]
Specificity	0.632	[0.391 ; 0.833]
Negative	0.706	[0.47 ; 0.917]

predictive value		
Positive predictive value	0.667	[0.444 ; 0.857]

336

337 Confidence results are calculated using a bootstrap. Due to the small number of observations,  
338 the 95% CI is quite wide. Comparison with load results was carried out using the McNemar  
339 test<sup>[39]</sup>. (Figure 1)



340

341 Figure 1: There is a significant difference between the results of the diagnostic accuracy of  
342 the load test (55.3 %) and the built model (68.4%), based on our study results. Obviously, the  
343 model has better predictive properties, P value = 0.0001.

344 The comparative statistical analysis demonstrated that the dltq\_01\_TpTe parameter has a  
345 statically significant difference between the two groups, in the first group, the mean  $\pm$  Std.  
346 Div.  $7.2 \pm 28.1$ , and in the second group, the mean  $\pm$  Std. Div.  $-12.2 \pm 20.0$ , p value=0.046.

### 347 **Discussion**

348 Using single channel ECG in the diagnosis of ischemic heart disease is a potential novel  
349 diagnostic strategy. The usage of single channel ECG in optimizing the physical stress test  
350 such as bicycle ergometry <sup>[1]</sup>. Additionally, single channel ECG results can be interpreted  
351 using machine learning models to increase the diagnostic accuracy and used as a novel risk  
352 score for future cardiovascular events <sup>[10]</sup>.

353 Several ongoing clinical trials to assess the reliability of single channel ECG in the diagnosis  
354 of ischemic heart disease and arrhythmia in both adults and children (NCT05756309,  
355 NCT06181799).

356 Using physical stress tested monitored 12 lead-ECG remains the elementary test for the  
357 primary detection of ischemic heart disease. However, severe limitations exist in the  
358 diagnostic accuracy related to the ECG artifact during the movement of the patients during  
359 the physical stress test.

360 Improving the diagnostic accuracy of the physical stress test is a point of focus of the  
361 cardiological scientific community. Several attempts performed to enhance the diagnosis  
362 performance of the physical exertion tests using complementary methods such as the  
363 dynamics of cardiac electrical activity (EAS) during exercise testing <sup>[40]</sup>. The study suggests  
364 that incorporating the equivalent electric cardiac generator of dipole type during exercise  
365 ECG testing can enhance the accuracy of diagnosing coronary artery disease <sup>[40]</sup>.

366 Previous clinical study using a Wearable wireless electrocardiographic (ECG) has shown that  
367 the single channel ECG has a poor sensitivity 8.3% (1.0–27.0%) and quite high specificity  
368 89.9% (80.2–95.8%) for detection of reversible ischemic heart disease <sup>[41]</sup>. The study  
369 concluded that both 12-lead ECG (sensitivity 12.5% (3.0–34.4%), specificity 91.3% (82.0–  
370 96.7%)) and the single channel ECG have poor clinical usefulness in terms of ability to detect  
371 ischemic heart disease. Interestingly, a dramatic difference has been observed in the II lead of  
372 the 12- lead ECG in compare to the single channel ECG <sup>[41]</sup>. However, other studies  
373 suggested the use of deep learning models to enhance the diagnostic accuracy (sensitivity) of  
374 the ECG for ischemic heart disease in emergency department <sup>[42]</sup>.

375 Advancements in single-channel ECG technology for the detection of ischemic heart disease  
376 demonstrated that machine learning models based on single-lead ECG and pulse wave  
377 parameters, along with age and gender, can simplify screening diagnostics of ejection fraction

378 decrease and diastolic dysfunction with high accuracy<sup>[37]</sup>. Furthermore, high-frequency ECG  
379 signals have shown increased sensitivity and early timing in diagnosing cardiac ischemia, and  
380 portable high-resolution ECG devices have demonstrated utility in acute emergency settings  
381 [43].

## 382 **Conclusions**

383 Single channel ECG (CARDO-QVARK ) have a potential to be used as an additional method  
384 for the diagnosis of ischemic heart disease in combination with the physical stress test  
385 including bicycle ergometry. Further studies required on a larger sample size needed to  
386 confirm the usage of the CARDO-QVARK for the clinical use for the diagnosis of ischemic  
387 heart disease.

388 The following CARDO-QVARK parameter are of interest for further investigation to reveal  
389 the hidden diagnostic value in the diagnosis of ischemic heart disease, dltq\_01\_Pan...31,  
390 dltq\_01\_SA, dltq\_01\_JA, dltq\_01\_TE1, and dltq\_01\_TpTe. Further, study on a larger sample  
391 is ongoing on clinicaltrials.gov (NCT06181799).

## 392 **List of abbreviations**

393 CVD; cardiovascular disease, CTP; stress computed tomography myocardial perfusion  
394 imaging

## 395 **Decelerations**

- 396 1. Ethics approval and consent to participate: the study approved by the Sechenov  
397 University, Russia, from “Ethics Committee Requirement № 19-23 from 26.10.2023”.  
398 A written consent is taken from the study participants
- 399 2. Consent for publication: applicable on reasonable request
- 400 3. Availability of data and materials: applicable on reasonable request
- 401 4. Competing interests: The authors declare that they have no competing interests  
402 regarding publication.
- 403 5. Funding’s: The work financed by the Ministry of Science and Higher Education of the  
404 Russian Federation within the framework of state support for the creation and  
405 development of World-Class Research Center ‘Digital biodesign and personalized  
406 healthcare’ № 075-15-2022-304.
- 407 6. Authors' contributions: MB is the writer, researcher, collected and analyzed data,  
408 interpreted the results, and revised the final version of the manuscript, MA, collected  
409 part of the patients, AS analyzed the exhaled breath, AS biostatistical analysis of the  
410 sample, PCh, DG, NV, NM, AAB, SVK, EF, revised the paper, and PhK revised the  
411 final version of the manuscript. All authors have read and approved the manuscript.

- 412 7. Acknowledgments: not applicable
- 413 8. Authors' information: **Basheer Abdullah Marzog**, World-Class Research Center  
414 «Digital Biodesign and Personalized Healthcare», I.M. Sechenov First Moscow State  
415 Medical University (Sechenov University), 119991 Moscow, Russia; postal address:  
416 Russia, Moscow, 8-2 Trubetskaya street, 119991. (marzug@mail.ru, +79969602820).  
417 ORCID: 0000-0001-5507-2413. Scopus ID: 57486338800. **Magomed Abdullaev**,  
418 World-Class Research Center «Digital Biodesign and Personalized Healthcare», I.M.  
419 Sechenov First Moscow State Medical University (Sechenov University), 119991  
420 Moscow, Russia; postal address: Russia, Moscow, 8-2 Trubetskaya street, 119991.  
421 ORCID: 0000-0002-0451-2009. email: m.ba.m@icloud.com. **Peter Chomakhidze**,  
422 World-Class Research Center «Digital Biodesign and Personalized Healthcare», I.M.  
423 Sechenov First Moscow State Medical University (Sechenov University), 119991  
424 Moscow, Russia; postal address: Russia, Moscow, 8-2 Trubetskaya street, 119991.  
425 ORCID: 0000-0003-1485-6072. email: m.ba.m@bk.ru. **Daria Gognieva**, World-Class  
426 Research Center «Digital Biodesign and Personalized Healthcare», I.M. Sechenov First  
427 Moscow State Medical University (Sechenov University), 119991 Moscow, Russia;  
428 postal address: Russia, Moscow, 8-2 Trubetskaya street, 119991. ORCID: 0000-0002-  
429 0451-2009. email: gognievad\_g@staff.sechenov.ru. **Nina Vladimirovna Gagarina**,  
430 University clinical Hospital number 1, Radiology department, I.M. Sechenov First  
431 Moscow State Medical University (Sechenov University), 119991 Moscow, Russia;  
432 postal address: Russia, Moscow, 8-2 Trubetskaya street, 119991. Scopus ID:  
433 6508312251. m.ba98@bk.ru. **Natalia Mozhukhina**, University clinical Hospital  
434 number 1, Health Management Clinic, I.M. Sechenov First Moscow State Medical  
435 University (Sechenov University), 119991 Moscow, Russia; postal address: Russia,  
436 Moscow, 8-2 Trubetskaya street, 119991. ORCID: 0009-0002-7334-6945.  
437 v.t.i.m.b@outlook.com. **Sergey Vladimirovich Kostin**, National Research Ogarev  
438 Mordovia State University. Russia, Republic of Mordovia, Saransk, Bolshevistskaya  
439 str., 68, Saransk, Mordovia Republic, 430005. email: drmosalah@mail.ru. **Alexander**  
440 **Suvorov**, World-Class Research Center «Digital Biodesign and Personalized  
441 Healthcare», I.M. Sechenov First Moscow State Medical University (Sechenov  
442 University), 119991 Moscow, Russia; postal address: Russia, Moscow, 8-2 Trubetskaya  
443 street, 119991. email: [suvorovayul@staff.sechenov.ru](mailto:suvorovayul@staff.sechenov.ru). **Afina Aftandilovna**  
444 **Bestavashvili**, World-Class Research Center «Digital Biodesign and Personalized  
445 Healthcare», I.M. Sechenov First Moscow State Medical University (Sechenov

446 University), 119991 Moscow, Russia; postal address: Russia, Moscow, 8-2 Trubetskaya  
447 street, 119991. email: [basheermarzoog1998@gmail.com](mailto:basheermarzoog1998@gmail.com). **Ekaterina Fominykha**,  
448 University clinical Hospital number 1, Radiology department, I.M. Sechenov First  
449 Moscow State Medical University (Sechenov University), 119991, Moscow, Russia;  
450 postal address: Russia, Moscow, 8-2 Trubetskaya street, 119991. ORCID: 0000-0003-  
451 0288-7656. Email: [Fominykhev@staff.sechenov.ru](mailto:Fominykhev@staff.sechenov.ru). **Philipp Kopylov**, director of the  
452 institute of the Research Center «Digital Biodesign and Personalized Healthcare», I.M.  
453 Sechenov First Moscow State Medical University (Sechenov University), 119991  
454 Moscow, Russia; postal address: Russia, Moscow, 8-2 Trubetskaya street, 119991.  
455 ORCID: 0000-0002-4535-8685. Scopus ID: 6507736224. email:  
456 [kopylovf\\_yu@staff.sechenov.ru](mailto:kopylovf_yu@staff.sechenov.ru)

457 9. The paper has not been submitted elsewhere

458

#### 459 **STANDARDS OF REPORTING**

460 STROBE guideline has been followed.

461

#### 462 **References**

- 463 [1] Marzoog, B. A. Breathomics Detect the Cardiovascular Disease: Delusion or Dilution  
464 of the Metabolomic Signature. *Curr. Cardiol. Rev.*, **2024**, *20* (4).  
465 <https://doi.org/10.2174/011573403X283768240124065853>.
- 466 [2] Abdou, A.; Krishnan, S. Horizons in Single-Lead ECG Analysis From Devices to  
467 Data. *Front. Signal Process.*, **2022**, *2*, 866047.
- 468 [3] Avram, R.; Ramsis, M.; Cristal, A. D.; Nathan, V.; Zhu, L.; Kim, J.; Kuang, J.; Gao,  
469 A.; Vittinghoff, E.; Rohdin-Bibby, L.; et al. Validation of an Algorithm for Continuous  
470 Monitoring of Atrial Fibrillation Using a Consumer Smartwatch. *Hear. Rhythm*, **2021**,  
471 *18* (9), 1482–1490. <https://doi.org/10.1016/j.hrthm.2021.03.044>.
- 472 [4] Perez, M. V.; Mahaffey, K. W.; Hedlin, H.; Rumsfeld, J. S.; Garcia, A.; Ferris, T.;  
473 Balasubramanian, V.; Russo, A. M.; Rajmane, A.; Cheung, L.; et al. Large-Scale  
474 Assessment of a Smartwatch to Identify Atrial Fibrillation. *N. Engl. J. Med.*, **2019**, *381*  
475 (20), 1909–1917. <https://doi.org/10.1056/NEJMoa1901183>.
- 476 [5] Tison, G. H.; Sanchez, J. M.; Ballinger, B.; Singh, A.; Olgin, J. E.; Pletcher, M. J.;  
477 Vittinghoff, E.; Lee, E. S.; Fan, S. M.; Gladstone, R. A.; et al. Passive Detection of  
478 Atrial Fibrillation Using a Commercially Available Smartwatch. *JAMA Cardiol.*, **2018**,  
479 *3* (5), 409–416. <https://doi.org/10.1001/jamacardio.2018.0136>.

- 480 [6] Inui, T.; Kohno, H.; Kawasaki, Y.; Matsuura, K.; Ueda, H.; Tamura, Y.; Watanabe,  
481 M.; Inage, Y.; Yakita, Y.; Wakabayashi, Y.; et al. Use of a Smart Watch for Early  
482 Detection of Paroxysmal Atrial Fibrillation: Validation Study. *JMIR Cardio*, **2020**, *4*  
483 (1). <https://doi.org/10.2196/14857>.
- 484 [7] Koshy, A. N.; Sajeev, J. K.; Nerlekar, N.; Brown, A. J.; Rajakariar, K.; Zureik, M.;  
485 Wong, M. C.; Roberts, L.; Street, M.; Cooke, J.; et al. Smart Watches for Heart Rate  
486 Assessment in Atrial Arrhythmias. *Int. J. Cardiol.*, **2018**, *266*, 124–127.  
487 <https://doi.org/10.1016/J.IJCARD.2018.02.073>.
- 488 [8] Nazarian, S.; Lam, K.; Darzi, A.; Ashrafian, H. Diagnostic Accuracy of Smartwatches  
489 for the Detection of Cardiac Arrhythmia: Systematic Review and Meta-Analysis. *J.*  
490 *Med. Internet Res.*, **2021**, *23* (8). <https://doi.org/10.2196/28974>.
- 491 [9] Fatimah, B.; Singh, P.; Singhal, A.; Pramanick, D.; Pranav, S.; Pachori, R. B. Efficient  
492 Detection of Myocardial Infarction from Single Lead ECG Signal. *Biomed. Signal*  
493 *Process. Control*, **2021**, *68*, 102678. <https://doi.org/10.1016/J.BSPC.2021.102678>.
- 494 [10] Issa, M. F.; Yousry, A.; Tuboly, G.; Juhasz, Z.; AbuEl-Atta, A. H.; Selim, M. M.  
495 Heartbeat Classification Based on Single Lead-II ECG Using Deep Learning. *Heliyon*,  
496 **2023**, *9* (7), e17974. <https://doi.org/10.1016/j.heliyon.2023.e17974>.
- 497 [11] Zhao, X.; Zhang, J.; Gong, Y.; Xu, L.; Liu, H.; Wei, S.; Wu, Y.; Cha, G.; Wei, H.;  
498 Mao, J.; et al. Reliable Detection of Myocardial Ischemia Using Machine Learning  
499 Based on Temporal-Spatial Characteristics of Electrocardiogram and  
500 Vectorcardiogram. *Front. Physiol.*, **2022**, *13*, 854191.  
501 <https://doi.org/10.3389/FPHYS.2022.854191/BIBTEX>.
- 502 [12] Smith, W. M.; Riddell, F.; Madon, M.; Gleva, M. J. Comparison of Diagnostic Value  
503 Using a Small, Single Channel, P-Wave Centric Sternal ECG Monitoring Patch with a  
504 Standard 3-Lead Holter System over 24 Hours. *Am. Heart J.*, **2017**, *185*, 67–73.  
505 <https://doi.org/10.1016/J.AHJ.2016.11.006>.
- 506 [13] Xintarakou, A.; Sousonis, V.; Asvestas, D.; Vardas, P. E.; Tzeis, S. Remote Cardiac  
507 Rhythm Monitoring in the Era of Smart Wearables: Present Assets and Future  
508 Perspectives. *Front. Cardiovasc. Med.*, **2022**, *9*, 853614.  
509 <https://doi.org/10.3389/FCVM.2022.853614/BIBTEX>.
- 510 [14] Krasteva, V.; Jekova, I.; Schmid, R. Perspectives of Human Verification via Binary  
511 QRS Template Matching of Single-Lead and 12-Lead Electrocardiogram. *PLoS One*,  
512 **2018**, *13* (5). <https://doi.org/10.1371/JOURNAL.PONE.0197240>.
- 513 [15] Attia, Z. I.; Harmon, D. M.; Dugan, J.; Manka, L.; Lopez-Jimenez, F.; Lerman, A.;




- 514 Siontis, K. C.; Noseworthy, P. A.; Yao, X.; Klavetter, E. W.; et al. Prospective  
515 Evaluation of Smartwatch-Enabled Detection of Left Ventricular Dysfunction. *Nat.*  
516 *Med.*, **2022**, 28 (12), 2497–2503. <https://doi.org/10.1038/s41591-022-02053-1>.
- 517 [16] Gu, H. Y.; Huang, J.; Liu, X.; Qiao, S. Q.; Cao, X. Effectiveness of Single-Lead ECG  
518 Devices for Detecting Atrial Fibrillation: An Overview of Systematic Reviews.  
519 *Worldviews on Evidence-Based Nursing*. John Wiley and Sons Inc 2023.  
520 <https://doi.org/10.1111/wvn.12667>.
- 521 [17] Rajakariar, K.; Koshy, A. N.; Sajeev, J. K.; Nair, S.; Roberts, L.; Teh, A. W. Accuracy  
522 of a Smartwatch Based Single-Lead Electrocardiogram Device in Detection of Atrial  
523 Fibrillation. *Heart*, **2020**, 106 (9), 665–670. [https://doi.org/10.1136/HEARTJNL-2019-](https://doi.org/10.1136/HEARTJNL-2019-316004)  
524 [316004](https://doi.org/10.1136/HEARTJNL-2019-316004).
- 525 [18] Sološenko, A.; Petrenas, A.; Paliakaite, B.; Sörmö, L.; Marozas, V. Detection of  
526 Atrial Fibrillation Using a Wrist-Worn Device. *Physiol. Meas.*, **2019**, 40 (2).  
527 <https://doi.org/10.1088/1361-6579/AB029C>.
- 528 [19] Fan, Y. Y.; Li, Y. G.; Li, J.; Cheng, W. K.; Shan, Z. L.; Wang, Y. T.; Guo, Y. T.  
529 Diagnostic Performance of a Smart Device with Photoplethysmography Technology  
530 for Atrial Fibrillation Detection: Pilot Study (Pre-Mafa II Registry). *JMIR mHealth*  
531 *uHealth*, **2019**, 7 (3). <https://doi.org/10.2196/11437>.
- 532 [20] Bumgarner, J. M.; Lambert, C. T.; Hussein, A. A.; Cantillon, D. J.; Baranowski, B.;  
533 Wolski, K.; Lindsay, B. D.; Wazni, O. M.; Tarakji, K. G. Smartwatch Algorithm for  
534 Automated Detection of Atrial Fibrillation. *J. Am. Coll. Cardiol.*, **2018**, 71 (21), 2381–  
535 [2388](https://doi.org/10.1016/J.JACC.2018.03.003). <https://doi.org/10.1016/J.JACC.2018.03.003>.
- 536 [21] Vardas, P.; Cowie, M.; Dargès, N.; Asvestas, D.; Tzeis, S.; Vardas, E. P.; Hindricks,  
537 G.; Camm, J. The Electrocardiogram Endeavour: From the Holter Single-Lead  
538 Recordings to Multilead Wearable Devices Supported by Computational Machine  
539 Learning Algorithms. *Europace*, **2020**, 22 (1), 19–23.  
540 <https://doi.org/10.1093/EUROPACE/EUZ249>.
- 541 [22] Bayoumy, K.; Gaber, M.; Elshafeey, A.; Mhaimed, O.; Dineen, E. H.; Marvel, F. A.;  
542 Martin, S. S.; Muse, E. D.; Turakhia, M. P.; Tarakji, K. G.; et al. Smart Wearable  
543 Devices in Cardiovascular Care: Where We Are and How to Move Forward. *Nat. Rev.*  
544 *Cardiol.*, **2021**, 18 (8), 581–599. <https://doi.org/10.1038/S41569-021-00522-7>.
- 545 [23] Nault, I.; André, P.; Plourde, B.; Leclerc, F.; Sarrazin, J. F.; Philippon, F.; O’Hara, G.;  
546 Molin, F.; Steinberg, C.; Roy, K.; et al. Validation of a Novel Single Lead Ambulatory  
547 ECG Monitor – Cardiostat<sup>TM</sup> – Compared to a Standard ECG Holter Monitoring. *J.*

- 548 *Electrocardiol.*, **2019**, *53*, 57–63.
- 549 <https://doi.org/10.1016/J.JELECTROCARD.2018.12.011>.
- 550 [24] Limitations of the Conventional ECG: Utility of Other Techniques. In *Clinical*
- 551 *Electrocardiography: A Textbook*; wiley, 2021; pp 552–570.
- 552 <https://doi.org/10.1002/9781119536475.ch25>.
- 553 [25] Braun, T.; Spiliopoulos, S.; Veltman, C.; Hergesell, V.; Passow, A.; Tenderich, G.;
- 554 Borggreffe, M.; Koerner, M. M. Detection of Myocardial Ischemia Due to Clinically
- 555 Asymptomatic Coronary Artery Stenosis at Rest Using Supervised Artificial
- 556 Intelligence-Enabled Vectorcardiography – A Five-Fold Cross Validation of Accuracy.
- 557 *J. Electrocardiol.*, **2020**, *59*, 100–105.
- 558 <https://doi.org/10.1016/j.jelectrocard.2019.12.018>.
- 559 [26] Beck, S.; Martínez Pereyra, V.; Seitz, A.; Bekerredjian, R.; Sechtem, U.; Ong, P.
- 560 Detection of ECG alterations typical for myocardial ischemia: New methods 2021.
- 561 *Internist*, **2021**. <https://doi.org/10.1007/s00108-021-01037-6>.
- 562 [27] Hilbel, T.; Frey, N. Review of Current ECG Consumer Electronics (Pros and Cons). *J.*
- 563 *Electrocardiol.*, **2023**, *77*, 23–28. <https://doi.org/10.1016/j.jelectrocard.2022.11.010>.
- 564 [28] Kuznetsova, N.; Gubina, A.; Sagirova, Z.; Dhif, I.; Gognieva, D.; Melnichuk, A.;
- 565 Orlov, O.; Syrkina, E.; Sedov, V.; Chomakhidze, P.; et al. Left Ventricular Diastolic
- 566 Dysfunction Screening by a Smartphone-Case Based on Single Lead ECG. *Clin. Med.*
- 567 *Insights Cardiol.*, **2022**, *16*. <https://doi.org/10.1177/11795468221120088>.
- 568 [29] Gognieva, D.; Vishnyakova, N.; Mitina, Y.; Chomakhidze, P.; Mesitskaya, D.;
- 569 Kuznetsova, N.; Khiari, M.; Ryabykina, G.; Boytsov, S.; Syrkin, A.; et al. Remote
- 570 Screening for Atrial Fibrillation by a Federal Cardiac Monitoring System in Primary
- 571 Care Patients in Russia: Results from the Prospective Interventional Multicenter
- 572 FECAS-AFS Study. *Glob. Heart*, **2022**, *17* (1). <https://doi.org/10.5334/gh.1057>.
- 573 [30] Sagirova, Z.; Kuznetsova, N.; Gogiberidze, N.; Gognieva, D.; Suvorov, A.;
- 574 Chomakhidze, P.; Omboni, S.; Saner, H.; Kopylov, P. Cuffless Blood Pressure
- 575 Measurement Using a Smartphone-Case Based ECG Monitor with
- 576 Photoplethysmography in Hypertensive Patients. *Sensors*, **2021**, *21* (10), 3525.
- 577 <https://doi.org/10.3390/s21103525>.
- 578 [31] Shirai, K.; Hiruta, N.; Song, M.; Kurosu, T.; Suzuki, J.; Tomaru, T.; Miyashita, Y.;
- 579 Saiki, A.; Takahashi, M.; Suzuki, K.; et al. Cardio-Ankle Vascular Index (CAVI) as a
- 580 Novel Indicator of Arterial Stiffness: Theory, Evidence and Perspectives. *J.*
- 581 *Atheroscler. Thromb.*, **2011**, *18* (11), 924–938. <https://doi.org/10.5551/jat.7716>.

- 582 [32] Cockcroft, D. W.; Gault, M. H. Prediction of Creatinine Clearance from Serum  
583 Creatinine. *Nephron*, **1976**, *16* (1), 31–41. <https://doi.org/10.1159/000180580>.
- 584 [33] Winter, M. A.; Guhr, K. N.; Berg, G. M. Impact of Various Body Weights and Serum  
585 Creatinine Concentrations on the Bias and Accuracy of the Cockcroft-Gault Equation.  
586 *Pharmacotherapy*, **2012**, *32* (7), 604–612. [https://doi.org/10.1002/j.1875-](https://doi.org/10.1002/j.1875-9114.2012.01098.x)  
587 [9114.2012.01098.x](https://doi.org/10.1002/j.1875-9114.2012.01098.x).
- 588 [34] Brown, D. L.; Masselink, A. J.; Lalla, C. D. Functional Range of Creatinine Clearance  
589 for Renal Drug Dosing: A Practical Solution to the Controversy of Which Weight to  
590 Use in the Cockcroft-Gault Equation. *Ann. Pharmacother.*, **2013**, *47* (7–8), 1039–  
591 1044. <https://doi.org/10.1345/aph.1S176>.
- 592 [35] Delgado, C.; Baweja, M.; Crews, D. C.; Eneanya, N. D.; Gadegbeku, C. A.; Inker, L.  
593 A.; Mendu, M. L.; Miller, W. G.; Moxey-Mims, M. M.; Roberts, G. V.; et al. A  
594 Unifying Approach for GFR Estimation: Recommendations of the NKF-ASN Task  
595 Force on Reassessing the Inclusion of Race in Diagnosing Kidney Disease. *Am. J.*  
596 *Kidney Dis.*, **2022**, *79* (2), 268-288.e1. <https://doi.org/10.1053/j.ajkd.2021.08.003>.
- 597 [36] Sagirova, Z. N.; Kuznetsova, N. O.; Suvorov, A. Y.; Gognieva, D. G.; Kulikov, V. M.;  
598 Chomakhidze, P. S.; Andreev, D. A.; Kopylov, P. Y. Assessment of Left Ventricular  
599 Systolic Function Using a Single-Channel ECG Monitor with Photoplethysmography  
600 Based on Machine Learning Models. *Kardiol. i serdechno-sosudistaya khirurgiya*,  
601 **2023**, *16* (1), 46. <https://doi.org/10.17116/kardio20231601146>.
- 602 [37] Kuznetsova, N.; Sagirova, Z.; Suvorov, A.; Dhif, I.; Gognieva, D.; Afina, B.;  
603 Poltavskaya, M.; Sedov, V.; Chomakhidze, P.; Kopylov, P. A Screening Method for  
604 Predicting Left Ventricular Dysfunction Based on Spectral Analysis of a Single-  
605 Channel Electrocardiogram Using Machine Learning Algorithms. *Biomed. Signal*  
606 *Process. Control*, **2023**, *86*, 105219. <https://doi.org/10.1016/j.bspc.2023.105219>.
- 607 [38] Cawley, G. C.; Talbot, N. L. C. On Over-Fitting in Model Selection and Subsequent  
608 Selection Bias in Performance Evaluation. *J. Mach. Learn. Res.*, **2010**, *11*, 2079–2107.
- 609 [39] Marius, O. U.; Happiness, O.-I. An Extended McNemar Test for Comparing  
610 Correlated Proportion of Positive Responses. *Biometrics Biostat. Int. J.*, **2019**, *8* (4),  
611 125–137. <https://doi.org/10.15406/bbij.2019.08.00281>.
- 612 [40] Kramm, M. N.; Strelkov, N. O.; Chomakhidze, P. S.; Kopylov, F. Y. Study of  
613 Additional Diagnostic Signs of Myocardial Ischemia. *Kardiol. i serdechno-sosudistaya*  
614 *khirurgiya*, **2016**, *9* (1), 52. <https://doi.org/10.17116/kardio20169152-57>.
- 615 [41] Fabricius Ekenberg, L.; Høfsten, D. E.; Rasmussen, S. M.; Mølgaard, J.; Hasbak, P.;

- 616 Sørensen, H. B. D.; Meyhoff, C. S.; Aasvang, E. K. Wireless Single-Lead versus  
617 Standard 12-Lead ECG, for ST-Segment Deviation during Adenosine Cardiac Stress  
618 Scintigraphy. *Sensors*, **2023**, 23 (6), 2962. <https://doi.org/10.3390/s23062962>.
- 619 [42] Lee, B. T.; Kwon, J.; Cho, J.; Bae, W.; Park, H.; Seo, W.-W.; Cho, I.; Lee, Y.; Park, J.;  
620 Oh, B.-H.; et al. Usefulness of Deep-Learning Algorithm for Detecting Acute  
621 Myocardial Infarction Using Electrocardiogram Alone in Patients With Chest Pain at  
622 Emergency Department: DAMI-ECG Study. *J. Cardiovasc. Interv.*, **2023**, 2 (2), 100.  
623 <https://doi.org/10.54912/jci.2022.0028>.
- 624 [43] Srinivasan, A.; Vijayalakshmi, K.; Padmanabhan, D.; Shanmugam, K. Early Detection  
625 of Ischaemia Through High Frequency ECGs: The Role of Medical-Grade Wearables  
626 for Chest Pain Triages. In *2022 IEEE International Conference on Electronics,  
627 Computing and Communication Technologies, CONECCT 2022*; Institute of Electrical  
628 and Electronics Engineers Inc.: B. M. S College of Engineering, Dept. of Ece,  
629 Karnataka, Bangalore, India, 2022.  
630 <https://doi.org/10.1109/CONECCT55679.2022.9865756>.
- 631

632 **Figure legends**



633

634 Figure 2: There is a significant difference between the results of the diagnostic accuracy of  
 635 the load test (55.3 %) and the built model (68.4%), based on our study results. Obviously, the  
 636 model has better predictive properties, P value = 0.0001.

637 **Table legends**

638 Table 5A: Categorical variables presented in absolute and relative values of the study for true  
 639 incidence of the stated factor. Abbreviations: CPT; stress myocardial perfusion computer  
 640 tomography imaging.  $\chi^2$  test used as a comparative test. \* Values statically significant  
 641 difference. Abbreviations: METs; metabolic equivalent.

Index	Factor	Group 1 (n=19). Positive CTP	Group 2 (n=19). Negative CTP	p

Gender	F	10 (52.6%)	7 (36.8%)	0.328
	M	9 (47.4%)	12 (63.2%)	
Obesity stage	1 degree	3 (15.8%)	3 (15.8%)	>0.999
	Normal	8 (42.1%)	9 (47.4%)	
	Overweight	8 (42.1%)	7 (36.8%)	
Atherosclerotic vascular (Namely)	Carotid	1 (9.1%)	0 (0.0%)	>0.999
	Carotid. Brachiocephalic bifurcation	10 (90.9%)	4 (100.0%)	
Stage of hypertension	I	2 (25.0%)	1 (7.1%)	0.179
	II	3 (37.5%)	11 (78.6%)	
	III	3 (37.5%)	2 (14.3%)	
Degree of hypertension	Degree 1	4 (50.0%)	7 (50.0%)	0.366
	Degree 2	1 (12.5%)	5 (35.7%)	
	Degree 3	3 (37.5%)	2 (14.3%)	
Risk of cardiovascular disease	High	3 (15.8%)	7 (36.8%)	0.486
	Low	7 (36.8%)	4 (21.1%)	
	Moderate	7 (36.8%)	7 (36.8%)	
	Very high	2 (10.5%)	1 (5.3%)	
Blood pressure reaction type on stress test	Asthenic	2 (10.5%)	1 (5.3%)	0.302
	Hypertonic	1 (5.3%)	1 (5.3%)	
	Hypotonic	3 (15.8%)	0 (0.0%)	
	Mild	1 (5.3%)	1 (5.3%)	

	Hypertonic			
	Normotonic	12 (63.2%)	16 (84.2%)	
Watt	75	4 (21.1%)	7 (36.8%)	0.167
	100	8 (42.1%)	2 (10.5%)	
	125	4 (21.1%)	3 (15.8%)	
	150	1 (5.3%)	2 (10.5%)	
	175	0 (0.0%)	2 (10.5%)	
	200	1 (5.3%)	3 (15.8%)	
	250	1 (5.3%)	0 (0.0%)	
Functional class by Watt	FC-I	2 (40.0%)	3 (42.9%)	>0.99
	FC-II	3 (60.0%)	4 (57.1%)	
Functional class by METs	FC-I	1 (20.0%)	3 (42.9%)	0.735
	FC-II	4 (80.0%)	3 (42.9%)	
	FC-III	0 (0.0%)	1 (14.3%)	
Reaction type to stress test (positive/negative)	Negative	8 (42.1%)	9 (47.4%)	0.593
	Positive	5 (26.3%)	7 (36.8%)	
	Suspected	6 (31.6%)	3 (15.8%)	
Reason of discontinuation of the stress test	Horizontal ST depression >1mm	2 (10.5%)	4 (21.1%)	0.660
	Reach goal HR	17 (89.5%)	15 (78.9%)	
Tolerance to exertion on stress test	Close to high	2 (10.5%)	2 (10.5%)	0.830
	High	2 (10.5%)	2 (10.5%)	
	Low	0 (0.0%)	1 (5.3%)	



	Moderate	13 (68.4%)	10 (52.6%)	
	Very high	2 (10.5%)	4 (21.1%)	
Biological estimated vascular age	High	10 (52.6%)	9 (47.4%)	0.746
	Normal	9 (47.4%)	10 (52.6%)	
CKD stage	I	6 (31.6%)	10 (52.6%)	0.078
	II	9 (47.4%)	9 (47.4%)	
	IIIa	4 (21.1%)	0 (0.0%)	

642

643 Table 1B: The continuous variables of the sample presented as a mean  $\pm$  standard deviation  
 644 (Std. div.), Student test as independent variables used. \* Values statically significant  
 645 difference. Abbreviations: SBP; systolic blood pressure, DBP; diastolic blood pressure, BMI,  
 646 body mass index, HR; heart rate, METs; metabolic equivalent, R-CAVI; right Cardio-ankle  
 647 vascular index, L-CAVI; left Cardio-ankle vascular index, RABI; right ankle-brachial index,  
 648 LABI; left ankle-brachial index, SBP B; systolic blood pressure brachial, DBP B; diastolic  
 649 blood pressure brachial, BP RB; blood pressure right brachial, BP RA ; blood pressure right  
 650 ankle, BP LA; blood pressure left ankle, BP A; blood pressure ankle, ABI; ankle-brachial  
 651 index, RTb; right brachial pulse, LTb; left brachial pulse, Tb; mean brachial pulse, Tba; mean  
 652 brachial-ankle pulse, Lha (cm); length heart-ankle, haPWV (m/s); heart-ankle pulse wave  
 653 velocity.

Index	Group 1 (n=19). Positive CTP. Mean $\pm$ Std. div.	Group 2 (n=19). Negative CTP. Mean $\pm$ Std. div.	p
Age	56.9 $\pm$ 6.2	60.6 $\pm$ 12.1	0.238
Pulse rest	73.2 $\pm$ 9.6	71.3 $\pm$ 11.1	0.578
SBP rest	124.4 $\pm$ 9.4	120.6 $\pm$ 14.8	0.354
DBP rest	79.1 $\pm$ 11.1	76.6 $\pm$ 8.2	0.429
Body weight	77.8 $\pm$ 17.4	74.0 $\pm$ 10.6	0.418

Height	173.2 ± 10.3	169.4 ± 8.9	0.2 40
BMI	25.8 ± 4.3	25.9 ± 4.1	0.9 39
Goal heart rate (HR)	163.1 ± 6.2	159.4 ± 12.1	0.2 38
Maximum HR	149.5 ± 11.2	146.7 ± 19.7	0.7 48
Reached % of the target HR on stress test	91.8 ± 8.2	92.6 ± 14.9	0.6 65
METs	6.7 ± 2.0	6.5 ± 2.1	0.7 15
Ejection fraction (%)	64.6 ± 4.1	65.3 ± 5.4	0.7 26
Biological estimated vessel age	58.1 ± 7.6	62.6 ± 13.9	0.2 22
R-CAVI	8.5 ± 0.8	9.1 ± 1.8	0.2 92
L-CAVI	8.5 ± 0.7	9.0 ± 1.7	0.2 31
RABI	1.2 ± 0.1	1.1 ± 0.1	0.1 81
LABI	1.2 ± 0.1	1.1 ± 0.1	0.0 82
Mean SBP B	130.1 ± 8.7	133.2 ± 16.2	0.4 65
Mean DBP B	82.9 ± 8.4	83.5 ± 9.0	0.8 17
BP RB (= (SBP+DBP)/2)	100.7 ± 10.0	102.8 ± 14.0	0.5 89
BP LB (= (SBP+DBP)/2)	101.8 ± 10.6	103.7 ± 12.7	0.6 31
Mean BP B= (BP RB+	101.3 ± 10.1	103.3 ± 13.2	0.6

BP LB )/2			03
BP RA (=(SBP+DBP)/2)	105.3 ± 10.7	108.3 ± 14.1	0.4 73
BP LA (=(SBP+DBP)/2)	106.6 ± 9.6	106.9 ± 11.1	0.9 26
Mean BP A= (BP RA + BP LA )/2	106.0 ± 9.6	107.6 ± 12.1	0.6 47
Mean ABI= (RABI+LABI)/2	1.2 ± 0.1	1.1 ± 0.1	0.1 01
RTb	79.4 ± 8.9	78.7 ± 11.5	0.8 39
LTb	73.3 ± 6.5	74.8 ± 10.7	0.5 99
Mean Tb =( RTb+ LTb)/2	76.3 ± 7.0	76.8 ± 10.8	0.8 88
Right Tba	88.5 ± 10.9	77.4 ± 22.1	0.1 25
Left Tba	87.7 ± 9.0	79.0 ± 20.8	0.1 44
Mean Tba =( Right Tba+ Left Tba)/2	88.1 ± 9.8	78.2 ± 21.3	0.1 29
Lha (cm)	150.8 ± 8.4	147.7 ± 7.2	0.2 40
haPWV (m/s)	0.9 ± 0.1	1.0 ± 0.2	0.2 34
β-stiffness index from PWV	3.0 ± 0.6	3.3 ± 1.2	0.6 86
Creatinine (μmol/L)	83.9 ± 11.9	86.4 ± 19.4	0.6 36
eGFR (2021 CKD-EPI Creatinine)	84.5 ± 13.7	79.6 ± 17.4	0.3 45

654

655

656 Table 6: The quality of the bicycle ergometry appeared quite low in our cohort.

Chars	Point estimate	95%CI
AUC	0.553	[0.406 ; 0.695]
Sensitivity	0.263	[0.067 ; 0.474]
Specificity	0.632	[0.409 ; 0.833]
Negative predictive value	0.462	[0.269 ; 0.654]
Positive predictive value	0.417	[0.143 ; 0.714]

657

658 Table 7: The 20 most statically significant features according to the build model. Dltq\_01  
 659 indicates the difference between the selected single channel ECG features immediately after  
 660 the stress minus the selected features before the stress test.

	Feature	Lasso absolute coefficient
21.	<b>dltq_01_Pan...31</b>	0.589804
22.	<b>dltq_01_SA</b>	0.509832
23.	<b>dltq_01_JA</b>	0.37366
24.	<b>dltq_01_TE1</b>	0.270038
25.	<b>dltq_01_TpTe</b>	0.258854
26.	<b>dltq_01_HFNoise</b>	0.248446
27.	<b>dltq_01_PpeakN</b>	0.206324
28.	<b>dltq_01_QRS11energy</b>	0.190459
29.	<b>dltq_01_TA</b>	0.15963
30.	<b>dltq_01_Sbeta</b>	0.150864
31.	<b>dltq_01_TE3</b>	0.138504
32.	<b>dltq_01_Tenergy</b>	0.125174
33.	<b>dltq_01_TE4</b>	0.116375
34.	<b>dltq_01_Tpenergy</b>	0.106516
35.	<b>dltq_01_QTc</b>	0.102957
36.	<b>dltq_01_TE2</b>	0.102495

37.	<b>dltq_01_HFQRS</b>	0.090197
38.	<b>dltq_01_SDNN</b>	0.082806
39.	<b>dltq_01_QRSE1</b>	0.082143
40.	<b>dltq_01_QRSw</b>	0.063462

661

662 Table 8: The quality of the single channel ECG in the diagnosis of ischemic heart disease  
663 using the CARDO-QVARK .

Chars	Point estimate	95%CI
AUC	0.684	[0.527 ; 0.817]
Sensitivity	0.737	[0.533 ; 0.929]
Specificity	0.632	[0.391 ; 0.833]
Negative predictive value	0.706	[0.47 ; 0.917]
Positive predictive value	0.667	[0.444 ; 0.857]

664

665

666